Press-release for stocks for takeda pharmaceutical company limited

Prices are updated after-hours

entities : Takeda pharmaceutical company limited source : Www.biospace.com

save search

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| 0.0% | O: 0.0% H: 0.0% C: 0.0%
entyvio fda disease active for therapy

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -7.07% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -9.68% | O: -0.07% H: 0.0% C: -0.96%
iclusig fda drug takeda approval application

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -8.49% | O: 0.21% H: 0.17% C: 0.14%
tak-079 positive topline potential results study

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -11.21% | O: 0.0% H: 0.47% C: 0.2%
vaccine dengue tak-003 qdenga

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -8.11% | O: 0.14% H: 0.35% C: 0.07%
XNCR | $18.385 -2.98% -3.07% 830K

Health Technology

| -7.02% | O: -3.56% H: 2.91% C: -3.34%
MOR | News | $17.96 -0.5% -0.5% 180K

Health Technology

| 4.15% | O: -0.4% H: 0.23% C: -0.46%
MGNX | $15.62 -2.8% -2.88% 1M

Health Technology

| -10.16% | O: -5.25% H: 2.94% C: 2.18%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -8.68% | O: 3.8% H: 1.1% C: -1.17%
financial

FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -7.65% | O: 0.07% H: 0.46% C: 0.42%
fda first treatment

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
Published: 2024-02-01 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -9.93% | O: 0.48% H: 0.0% C: -1.98%
fy2023 management momentum growth

Takeda Announces Chief Financial Officer Succession
Published: 2024-02-01 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -9.93% | O: 0.48% H: 0.0% C: -1.98%
financial

Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -9.93% | O: 0.38% H: 0.78% C: 0.78%
hyqvia approved therapy

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -10.42% | O: -0.27% H: 0.07% C: -0.07%
EXEL | $22.51 0.09% 0.09% 2.3M

Health Technology

| 4.14% | O: 0.14% H: 1.4% C: -0.23%
ntact-02 asco cancer trial results

Takeda Named Global Top Employer for Seventh Consecutive Year
Published: 2024-01-18 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -11.51% | O: -0.13% H: 0.27% C: 0.2%
year global

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -11.33% | O: -0.27% H: 0.61% C: -0.2%
ohb-607 license group oak agreement therapy

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -3.94% | O: 2.05% H: 0.29% C: 0.0%
livtencity approval cytomegalovirus treatment china

Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA Treatment for Rare form of Emphysema
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -4.57% | O: 0.36% H: 0.14% C: -1.01%
rare services glassia contract treatment blood

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -6.41% | O: -0.64% H: 0.21% C: -1.79%
hyqvia chmp positive therapy

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
Published: 2023-11-27 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -6.34% | O: 0.0% H: 0.42% C: 0.21%

FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -6.14% | O: 0.07% H: 0.57% C: 0.0%
cancer treatment

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -3.66% | O: 1.03% H: 0.73% C: 0.58%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -1.25% | O: -1.09% H: 1.03% C: 0.91%
XNCR | $18.385 -2.98% -3.07% 830K

Health Technology

| 9.16% | O: 1.32% H: 0.45% C: -1.19%
MOR | News | $17.96 -0.5% -0.5% 180K

Health Technology

| 122.29% | O: 2.22% H: 0.6% C: -9.4%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -2.85% | O: -0.28% H: 1.0% C: -0.46%
presentation meeting

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
Published: 2023-11-02 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology